Clinical Trials
- Melanoma
R3767-ONC-22122: A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab Versus Relatilimab and Nivolumab in Participants with Unresectable or Metastatic Melanoma
- Kidney Cancer, Head and Neck Cancers, Lung Cancer, Melanoma
XTX301 in Patients With Advanced Solid Tumors
- Kidney Cancer, Melanoma
A Phase 1/2a, Open-Label, Dose-Escalation and Dose-Expansion First-In-Human Study of the Safety, Tolerability, Activity, and Pharmacokinetics of REGN10597 (Anti PD-1-IL2RA-IL2 Fusion Protein) in Patients With Advanced Solid Organ Malignancies
- Phase 1 Cancers
A Phase 1 Study of ASP1002 in Participants With Metastatic or Locally Advanced Solid Tumors